Hydrocortisone - Diurnal

Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Chronocort; Hydrocortisone extended release - Diurnal; Infacort

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diurnal
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenal insufficiency
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adrenal insufficiency; Congenital adrenal hyperplasia

Most Recent Events

  • 23 Nov 2017 Phase I development in Adrenal-insufficiency (In volunteers) is ongoing in United Kingdom (PO, Controlled release)
  • 23 Nov 2017 Diurnal plans a phase I bioavailability trial for Adrenal insufficiency (In volunteers) in United Kingdom in January 2018 (NCT03343327)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Adrenal-insufficiency(In volunteers) in United Kingdom (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top